Filing Details
- Accession Number:
- 0001048477-24-000075
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-06 16:45:20
- Reporting Period:
- 2024-05-02
- Accepted Time:
- 2024-05-06 16:45:20
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1380710 | Eric George Davis | C/O Biomarin Pharmaceutical Inc. 770 Lindaro Street San Rafael CA 94901 | Evp, Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-04-30 | 301 | $68.65 | 56,157 | No | 5 | A | Direct | |
Common Stock | Acquisiton | 2024-05-02 | 1,850 | $63.10 | 58,007 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-05-02 | 1,850 | $85.01 | 56,157 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 5 | A | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy Common Stock) | Disposition | 2024-05-02 | 1,850 | $0.00 | 1,850 | $63.10 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
40,850 | 2014-12-04 | 2024-06-30 | No | 4 | M | Direct |
Footnotes
- Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
- Trade made pursuant to a 10b5-1 plan executed on September 13, 2023.
- The price in column 4 is the weighted average price. The purchase price actually received ranged from $85.00 to $85.03. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- Reflects the number of options outstanding after the transactions from this specific stock option grant.